2 news items
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
ARVN
PFE
16 May 24
of IBRANCE; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
ARVN
NVS
7 May 24
by proceeds from the exercise of stock options of $1.8 million. Research and Development Expenses: Research and development
- Prev
- 1
- Next